Navigation Links
Oncothyreon Reports First Quarter 2008 Financial Results
Date:5/7/2008

BELLEVUE, WA, May 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported a net loss of $5.1 million or $0.26 per basic and diluted share for the quarter ended March 31, 2008, compared with $4.7 million or $0.24 per basic and diluted share for the comparable period in 2007. All results are in U.S. dollars.

Total revenue was $2.0 million in the first quarter of 2008, compared to $0.2 million for the same period in 2007. The increase of $1.8 million reflects the increased sale of clinical trial material to Merck KGaA to support the Phase 3 trial of Stimuvax.

Expenses for the quarter ended March 31, 2008, were $7.1 million, compared with $4.8 million for the comparable period in 2007. The increase in operating expenses of $2.3 million resulted from an increase in manufacturing and sale of Stimuvax for the Phase 3 clinical trial of $2.1 million and an increase in general and administrative expense of $0.8 million arising from professional and consulting fees. Partially offsetting this increase were reductions in research and development expense and marketing and business development expense of $0.7 million and $0.5 million respectively.

As of March 31, 2008, Oncothyreon's cash, cash equivalents and short term investments were $16.5 million, compared to $24.2 million at the end of 2007, a decrease of $7.7 million, or 31.8 percent. Major contributors to the net change included $5.1 million used in operations, an increase in inventory and accounts receivable totaling $2.0 million and a decrease in accounts payable and accrued liabilities of $1.5 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

Oncothyreon's financial guidance is unchanged from that reported with the Company's 2007 financial results. For
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon files investigational new drug application for PX-866 oncology compound
2. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
3. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
4. Oncothyreon announces effectiveness of shelf registration statement
5. Oncothyreon announces issuance of patent for PX-867
6. Oncothyreon to present at upcoming investment conferences
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
9. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
10. Oncothyreon launches new corporate website
11. Oncothyreon to present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... Available in select spas in the ... Fleur’s introduces CC CRÈME Perfect Skin ... makeup, skin care and solar protection in one ... with specific complexion-correcting pigments to instantly blur flaws ... healthy glow. Far more than a concealer, it ...
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... Stem Cell Therapy Better Option for Humans, ... in English,for the first time, The British Institute ... Therapy) training to U.S. medical and,homeopathic practitioners for ... Plant stem cell therapy is more advantageous because,it ...
... Jan. 28 /PRNewswire-FirstCall/ - Quest PharmaTech Inc.,("Quest" ... has signed a,collaborative research agreement with the ... combination therapy for the treatment of lung ... lead oncology product,SL052, with various immunotherapeutic agents. ...
... Phytomedics Inc., a clinical,stage biopharmaceutical company developing novel ... will present at the,Wachovia 2008 Healthcare Conference in ... ET., Among the topics of the presentation ... business developments, including Phase III development,activities related to ...
Cached Biology Technology:Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 3
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Friday, April 20, 2012 Researchers from Cleveland ... greater consumption of sugar-sweetened and low-calorie sodas is associated ... caffeinated or decaffeinated coffee was associated with a lower ... American Journal of Clinical Nutrition is ...
... On the second anniversary of the Deepwater Horizon blowout, ... scientist Samantha Joye is urging the federal government to reassess ... occur in the future. The 22 researchers, whose paper ... , noted that the 2010 Deepwater Horizon oil spill was ...
... 19, 2012 From cognitive neuroscience to theoretical ... Research Fellows from the University of Houston (UH) ... ranging from medicine to energy. Recognizing ... in NSF-supported science, technology, engineering and mathematics disciplines, ...
Cached Biology News:Study finds soda consumption increases overall stroke risk 2Marine scientists urge government to reassess oil spill response 2Marine scientists urge government to reassess oil spill response 3Marine scientists urge government to reassess oil spill response 45 NSF Graduate Research Fellowships awarded to UH students, alumna 25 NSF Graduate Research Fellowships awarded to UH students, alumna 3
... bioassays for interferons are cytopathic effect inhibition ... assays. The neutralization assay measures the ... of the cytokine. Sample types include; tissue ... In these assays, one unit is defined ...
... and Protein G bind specifically to Fc ... and Protein G conjugates are commonly used ... and immunoglobulin subtypes from serum, hybridoma ascites ... fluids. These reagents are also commonly used ...
... complete, flexible system designed specifically for ... is frequently required in biological research. ... miniature Clark-style polarographic electrode. Measuring only ... (3.2 mm), it is ideal for ...
... is a member of the family of human cullin ... to the S. cerevisiae cdc53 gene. Cullin-3 is proposed ... forms a tight complex with cyclin E and targets ... protesomes. Cyclin E is an activator of cdk2, which ...
Biology Products: